Navigation Links
Questcor Reports Third Quarter 2010 Results
Date:10/28/2010

ANAHEIM, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today reported financial results for the quarter ended September 30, 2010. Net sales totaled $31.3 million and net income was $11.5 million or $0.18 per diluted common share for the quarter ended September 30, 2010. The Company's financial performance was driven primarily by an increase in net sales for Acthar in the treatment of acute exacerbations of multiple sclerosis (MS). Acthar net sales for the treatment of infantile spasms (IS) continued to be within its historic range.

In the third quarter of 2009, the Company reported net income of $1.2 million or $0.02 per diluted common share on net sales of $13.9 million. Questcor's financial results in the third quarter of 2009 were negatively affected by the combination of a lower number of prescriptions for the treatment of IS, unusually high amounts of Medicaid rebates related to Acthar usage in previous quarters, and rebate reserves related to usage by the Tricare pharmacy network.

In the second quarter of 2010, the Company reported net income of $9.3 million or $0.14 per diluted common share on net sales of $28.3 million.

"The third quarter of 2010 results reflect the continued execution of our straightforward growth strategy for Acthar," said Don M. Bailey, President and CEO of Questcor. "We continue to have success in educating neurologists about the benefits of Acthar for patients afflicted with acute exacerbations of MS who have medical issues with steroids, the first-line treatment for this condition.

"With the recent approval from the FDA to market Acthar for the treatment of infantile spasms, we have initiated our commercial efforts in this therapeutic area," continued Mr. Bailey. "Importantly, the approval of Acthar as a treatment for IS also resulted in an updated and modernized label that allows fo
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Questcor Reports Solid Fourth Quarter Results
2. Questcor to Discuss Results From FDA Panel Meeting
3. Trading Halted Today in Questcor Pharmaceuticals Common Stock
4. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
5. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Questcor to Present at UBS Global Life Sciences Conference
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... BerGenBio AS, a biopharmaceutical company ... cancers, today announces that it has raised NOK90 million ... and existing investors. BerGenBio will use the ... its pipeline of innovative cancer therapeutics, in particular an ... BGB324, a first-in-class selective Axl kinase inhibitor, which is ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
... , THOUSAND OAKS, Calif., Sept. 21 ... from a Phase 3 trial evaluating denosumab administered subcutaneously versus ... treatment of bone metastases in 1,776 advanced cancer patients with ... myeloma. These results were presented today at the 2009 ...
... MADISON, Conn., Sept 18 Further results from the initial clinical ... treatment for varicose veins, will be delivered on Friday, September 25, ... Philadelphia. The device combines mechanical and chemical modalities to accomplish vein ... is Steve Elias MD FACS FACPh, Associate Professor of Surgery at ...
Cached Medicine Technology:Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 2Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 3Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 4Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 5Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 6Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 7Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 8Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 9ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... CREEK, Calif., March 4 Longs Drug,Stores Corporation (NYSE: ... a quarterly cash dividend on common shares of $0.14 per ... the close of,business on March 11, 2008., About the ... (NYSE: LDG ) is one of the most recognized ...
... produced another article [1], which probably marks the opening ... of a further 2.4-year follow-up (after cessation of the ... P) cohort are reported. They concluded that, by the ... newly formed and unvalidated tool used in the WHI ...
... - Second Phase III clinical trial to begin ... 4 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. (TSX: BNC), ... it has received notice from,the U.S. Food and ... bladder cancer meets the criteria for Fast Track,designation. ...
... continued need for mammograms , , TUESDAY, March 4 (HealthDay News) ... woman stops taking combination hormone replacement therapy, a new study ... issue of the Journal of the American Medical Association ... Initiative (WHI). That trial was halted abruptly in 2002, when ...
... G.,Rendell,s health care team today told a state ... Pennsylvanians continues to grow and, with the,addition of ... there are,funds to pay for providing the uninsured ... the House of Representatives Appropriations,Committee that continuing the ...
... annual KID,HEALTHY--Steps to Healthy Living Campaign, SANTA ... trend of childhood obesity in Southern California schools, ... parents from Los Angeles,Orange, Riverside, San Bernardino, San ... participate in the KID HEALTHY--Steps to Healthy,Living Campaign. ...
Cached Medicine News:Health News:Health risks after cessation of postmenopausal hormone therapy 2Health News:Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy 2Health News:Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy 3Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 3Health News:Governor Rendell's Health Care Reform Cabinet Says Providing Access to Health Care for Pennsylvania's Uninsured is Within Reach 2Health News:Governor Rendell's Health Care Reform Cabinet Says Providing Access to Health Care for Pennsylvania's Uninsured is Within Reach 3Health News:Governor Rendell's Health Care Reform Cabinet Says Providing Access to Health Care for Pennsylvania's Uninsured is Within Reach 4Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 2Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 3
... An external computer-enhanced microplate reader ... provides automated flexible and rapid ... for accurate and reliable photometric ... or without shaking before reading) ...
... a number of assay steps for ... simple to use benchtop device. The ... stand-alone device but also provides easy ... and standard add-on modules provide maximum ...
... AP-22 Micro Plate Processor is ... Automated Microplate Analyzer. It has been ... assigned area can be customised according ... Micro Plate Processor is able to ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
Medicine Products: